Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars User Fees Review Pathway

BsUFA III Talks Could Move Cloud-Platform Goals Forward

  • Analysis

Executive Summary

US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.

You may also be interested in...



New GDUFA Workload Formula Will Not Include Inspections Until FY 2025 Fee-Setting

Capacity planning adjustment that will help calculate generic drug user fees will not include inspections at first to allow more time for time reporting system implementation.

New GDUFA Workload Formula Will Not Include Inspections Until FY 2025 Fee-Setting

Capacity planning adjustment that will help calculate generic drug user fees will not include inspections at first to allow more time for time reporting system implementation.

Califf: More Learning Necessary During Generic Drug Lifecycle

The US FDA commissioner called for enhancements to postmarketing data collection and analysis for generic drugs.

Table

View full table

Related Content

Generics Bulletin
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
Biosimilars User Fees Review Pathway
Latest Headlines

US FDA Complete Response Letter Rates Vary With Sponsor Size

Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?

Supplemental Filings: Califf Discusses Revolving Door; Poll Examines Public Trust In FDA Approvals

Recent And Upcoming FDA Advisory Committee Meetings

See All
UsernamePublicRestriction

Register

PS144270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By